Clinical trials: malaria
Malaria, Plasmodium Falciparum
A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK
This is an open label, single-site, first-in-human, dose-escalation Phase Ia study to assess safety and immunogenicity of the Plasmodium falciparum malaria vaccine candidate Pfs48/45 in Matrix-M adjuvant in healthy adults living…
- Trial name
- NCT05400746
- Testing
- Pfs48/45 in Matrix-M
- Where
- United Kingdom
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Vivax Malaria
Study on the Treatment of Vivax Malaria
This is a randomised open label trial with follow up for 1 year. 660 adults and children above 6 months diagnosed with acute Plasmodium vivax will be randomised into 3 groups, either chloroquine, artesunate, or…
- Trial name
- VHX (NCT01074905)
- Testing
- Artesunate, Chloroquine, Chloroquine/Primaquine
- Where
- Thailand
- Volunteers
- 655 people
- Sponsor
- University of Oxford
Malaria
Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults
Background: Malaria is a disease carried by mosquitoes in tropical countries around the world. It can cause symptoms like fever, body aches, and weakness.
- Trial name
- NCT05913973
- Testing
- Pvs230D1-EPA/Matrix-M
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Safety and Immunogenicity of Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545])
This study will be the first time that the candidate malaria vaccine Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]) will be tested in malaria endemic populations.
- Trial name
- NCT00431808
- Testing
- Malaria vaccine AMA1 (PfAMA-1-FVO[25-545], AMA1
- Where
- Mali
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- African Malaria Network Trust
Malaria, Public Health
Evaluation of a New Malaria Control Strategy Amongst Gold Miners Working Illegally in French Guiana (Malakit)
Illegal gold miners in French Guiana, a French overseas territory ('département') located in Amazonia, often carry malaria parasites (up to 46.8%).
- Trial name
- MALAKIT (NCT03695770)
- Testing
- kit for self-diagnosis and self-treatment
- Where
- 2 sites in Brazil, Suriname
- Volunteers
- 3,733 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier de Cayenne
Malaria Vivax
Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."
Phase 1 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of a malaria vaccine named Vivaxin against the protozoan Plamodium vivax in participants with no prior malaria infection
- Trial name
- Vivaxin-001 (NCT07172724)
- Testing
- Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory
- Where
- Brazil
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Malaria, Mosquito Repellent
Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Ethiopia
The combined use of a mosquito repellent and long lasting insecticidal nets (LLINs) by household members would result in a 40% reduction in malaria prevalence compared with households that only use LLINs.
- Conditions
- Malaria, Mosquito Repellent, Long Lasting Insecticidal Nets
- Trial name
- NCT01160809
- Testing
- Mosquito repellent
- Where
- Ethiopia
- Volunteers
- 6,082 people, healthy volunteers welcome
- Sponsor
- Malaria Consortium, Ethiopia
Malaria, Falciparum, HIV Infections
Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania
As HIV/AIDS is spreading in malaria-endemic countries, many patients here will need concomitant treatment for both infections. Effective combination treatments are available for both malaria (artemisinin-based combination…
- Trial name
- InterACT (NCT00885287)
- Testing
- Artemether-lumefantrine (AL)
- Where
- Tanzania
- Volunteers
- 830 people
- Sponsor
- University of Copenhagen
Malaria,Falciparum
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants
This four-cohort, first-in-human, healthy participant study aims to assess the test medicine's safety and tolerability, including injection site reactions and how it is taken up by the body when given as a single dose.
- Trial name
- NCT06558643
- Testing
- MMV371 LAI
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Falciparum Malaria
Clinical Evaluation of Long-term Sequelae in Patients With Severe Plasmodium Falciparum Malaria
Malaria, endemic in 85 countries, remains a major concern. By 2022, there will be 249 million cases and 608,000 deaths, 94% of them in Africa.
- Trial name
- SMAEE (NCT06992297)
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Malaria
MULTIple Doses of IPTi Proposal: a Lifesaving High Yield Intervention
As efforts to control malaria are stalling, and the disease is particularly severe in children under the age of two, it is imperative for countries in sub-Saharan Africa, with areas of moderate-to-high transmissions, to implement…
- Trial name
- MULTIPLY (NCT05085340)
- Testing
- Intermittent preventive treatment of malaria in infants (IPTi) with sulfadoxine-pyrimethamine (SP)
- Where
- 3 sites in Mozambique, Sierra Leone and 1 more
- Volunteers
- 94,252 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
Malaria, Falciparum
Arginine Malaria Trial: Study of Adjunctive Arginine in Falciparum Malaria
Acute falciparum malaria is associated with low plasma arginine and impaired nitric oxide (NO) production. Both are associated with poor outcome.
- Trial name
- NCT00147368
- Testing
- intravenous (IV) arginine
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Menzies School of Health Research
Malaria
Reducing the Effects of Malaria in Children by Administering Repeated Preventive Doses
The general goal of the project is to assess the infectious status and immunity of mothers and children living in a malaria region.
- Trial name
- NCT00167843
- Testing
- sulfadoxine-pyrimethamine
- Where
- Gabon
- Volunteers
- 1,189 people, healthy volunteers welcome
- Sponsor
- Albert Schweitzer Hospital
Whooping Cough, Malaria
Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal
Longitudinal survey in Northern Senegal to investigate the environmental factors modulating the immune response to childhood vaccines and to malaria.
- Conditions
- Whooping Cough, Malaria, Malnutrition
- Trial name
- AnoPalAnoVac (NCT01545115)
- Where
- Senegal
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- Biomedical Research Center EPLS
Uncomplicated Plasmodium Knowlesi Malaria
P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine
Preliminary studies have supported the background efficacy of local standard anti-malarial medications in the treatment of uncomplicated knowlesi malaria, however this has not been tested systematically and there are no current…
- Trial name
- ACT KNOW (NCT01708876)
- Testing
- Artesunate-mefloquine, Chloroquine, Primaquine
- Where
- 3 sites in Malaysia
- Volunteers
- 250 people
- Sponsor
- Menzies School of Health Research
Malaria
Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds
Open-label, randomized, microdose study
- Trial name
- NCT03436160
- Testing
- WR826647, WR909388, WR909390
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria, HIV Infections
HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children
HIV and malaria are major causes of morbidity and mortality in Sub-Saharan Africa and children bear the greatest brunt of both diseases. No single existing intervention is likely to control malaria in Africa.
- Trial name
- PROMOTE-PEDS (NCT00978068)
- Testing
- Lopinavir/Ritonavir (LPV/r), Nevirapine (NVP), Efavirenz (EFV)
- Where
- Uganda
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria (Plasmodium Falciparum)
Controlled Human Malaria Infection by Mosquito Bites Using a Local Strain of Plasmodium Falciparum
The project aims to reproduce the malaria infection cycle using African mosquitoes, namely Anopheles gambiae and a local strain of Plasmodium parasites.
- Trial name
- BB-LaCHMI-01 (NCT07816497)
- Testing
- Controlled Human Malaria Infection
- Where
- Gabon
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Pregnancy Malaria
Assessing to What Extent Dhps-431V Mutation May Influence the Protective Efficacy of IPTp-SP
Malaria in pregnancy (MiP) continues to be a significant public health issue, particularly in sub-Saharan Africa. The coverage of pregnant women with three or more doses of intermittent preventive treatment using…
- Trial name
- DEEM-FIT (NCT04634695)
- Where
- 2 sites in Nigeria
- Volunteers
- 288 people
- Sponsor
- Obafemi Awolowo University
Acute Falciparum Malaria
Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia
Background: Malaria is an illness caused by a parasite that enters people s bodies when a mosquito bites them. It can cause fevers, headaches, body aches, and weakness. If not treated, it can make some people very ill.
- Trial name
- NCT02612545
- Testing
- Dihydroartemisinin-piperaquine (DHA-PPQ), Mefloquine (MQ)
- Where
- Cambodia
- Volunteers
- 216 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.